The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma

Matthew J Rees¹, Ashish Panigrahi², Simon J Harrison^{2

3}, Andrew Spencer⁴, Tiffany Khong⁴, Simon Gibbs^{4

5}, Jay Hocking^{4

5}, Andrew Grigg⁶, Daniela Zantomio⁶

Affiliations

¹ Department of Clinical Haematology, Austin Health, Melbourne, VIC, Australia. Matthew.Rees.MD@gmail.com.
² Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
³ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
⁴ Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia.
⁵ Department of Haematology, Eastern Health, Melbourne, VIC, Australia.
⁶ Department of Clinical Haematology, Austin Health, Melbourne, VIC, Australia.

Matthew J Rees et al. Bone Marrow Transplant. 2022 Jun.

. 2022 Jun;57(6):1001-1003.

doi: 10.1038/s41409-022-01647-0. Epub 2022 Mar 28.

Matthew J Rees¹, Ashish Panigrahi², Simon J Harrison^{2

3}, Andrew Spencer⁴, Tiffany Khong⁴, Simon Gibbs^{4

5}, Jay Hocking^{4

5}, Andrew Grigg⁶, Daniela Zantomio⁶

¹ Department of Clinical Haematology, Austin Health, Melbourne, VIC, Australia. Matthew.Rees.MD@gmail.com.
² Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
³ Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
⁴ Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia.
⁵ Department of Haematology, Eastern Health, Melbourne, VIC, Australia.
⁶ Department of Clinical Haematology, Austin Health, Melbourne, VIC, Australia.

No abstract available

References

1. Turunen A, Silvennoinen R, Partanen A, Valtola J, Siitonen T, Putkonen M, et al. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study. Transfusion. 2021;61:1830–44. - DOI
1. Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transpl. 2008;14:116–24. - DOI
1. Schmidmaier R, Oversohl N, Schnabel B, Straka C, Emmerich B. Helper T cells (CD3+ /CD4+) within the autologous peripheral blood stem cell graft positively correlate with event free survival of multiple myeloma patients. Exp Oncol. 2008;30:240–3. - PubMed
1. Rees MJ, Mollee P, Ng JY, Murton A, Gonsalves JF, Panigrahi A, et al. The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. Bone Marrow Transpl. 2021;56:2152–9. - DOI
1. Lee SE, Lim JY, Kim TW, Ryu DB, Park SS, Jeon YW, et al. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. J Immunother Cancer. 2019;7:35. - DOI